Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 30 September 2024 AM
Roughly half of the 24 drugs recommended by the PBAC in July 2024 are officially on the road to government subsidy after their sponsors gave notice of intent, but some are moving quicker than others.
At the head of the que is a new formulation of Pfizer's chemotherapeutic Methoblastin. The genericised medication is the only drug recommended at the meeting that has reached the 'agreement to listing arrangements' stage.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.